Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2012
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Jonathan Mayito, et al.
Nature Communications|January 3, 2024
The evolution of centriole degradation in mouse spermSushil Khanal, Ankit Jaiswal, Rajanikanth Chowdanayaka, et al.
AIDS Research and Human Retroviruses|June 1, 2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIVRoss D Cranston, Charlene S Dezzutti, Aaron Siegel, et al.
The Journal of Antimicrobial Chemotherapy|February 26, 2013
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoringAlan Winston, Sophie Jose, Sara Gibbons, et al.
The Lancet. HIV|September 24, 2016
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessmentIan McGowan, Charlene S Dezzutti, Aaron Siegel, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2012
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Jonathan Mayito, et al.
Nature Communications|January 3, 2024
The evolution of centriole degradation in mouse spermSushil Khanal, Ankit Jaiswal, Rajanikanth Chowdanayaka, et al.
AIDS Research and Human Retroviruses|June 1, 2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIVRoss D Cranston, Charlene S Dezzutti, Aaron Siegel, et al.
The Journal of Antimicrobial Chemotherapy|February 26, 2013
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoringAlan Winston, Sophie Jose, Sara Gibbons, et al.
The Lancet. HIV|September 24, 2016
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessmentIan McGowan, Charlene S Dezzutti, Aaron Siegel, et al.
Pageof 15